top of page
Search


Apotek Selected for NSF I-Corps Spark Cohort on AI/ML and Cancer Care
Translating AI-powered research into real-world cancer impact Apotek Joins NSF I-Corps Spark Special Cohort on AI/ML and Cancer Care Taipei | [November 12, 2025] — Vizuro is proud to announce that our Apotek platform has been selected for the National Science Foundation (NSF) I-Corps Spark Cohort , beginning November 13, 2025 . This specialized program focuses on AI/ML-powered innovations in cancer research and care , empowering teams to translate cutting-edge science into
Esther Chen
Nov 112 min read


Vizuro and NCKU Forge Partnership to Accelerate AI-Driven Biologics Innovation
Partnership with Professor Woei-Jer Chuang of NCKU to explore AI-powered discovery in protein drug design Vizuro Apotek AI Drug Discovery Platform x Industry-Academia Collaboration with NCKU Taipei | [October 27, 2025] — Vizuro LLC, a leading innovator in multimodal causal AI and generative AI for drug discovery, today announced the signing of a Memorandum of Understanding (MOU) with Professor Woei-Jer Chuang, Ph.D., of the Department of Biochemistry and Molecular Biology, Na
Esther Chen
Oct 262 min read


Beyond Correlation: Apotek’s Causal Path Platform for Smarter Target Identification in Drug Discovery
Author: Chin-Lin Chen, Ph.D / Data Scientist at Vizuro Key Takeaway Drug discovery has entered the era of big data. Every year, thousands of disease and normal samples are profiled — yet one critical bottleneck remains: identifying clinically meaningful target–marker gene pairs for new drug development . The core value of Apotek Path is for this purpose: Identify disease-relevant targets → Causal modeling reveals mechanistic gene interactions tailored to your disease contex
Chin-Lin Chen
Sep 265 min read


From Correlation to Causation: Why Pharma Is Embracing Causal AI
Why causal AI is becoming pharma’s next strategic differentiator — from target validation to clinical trials and real-world evidence. Visualizing the Ladder of Causation in Pharma: from seeing correlations, to doing interventions, to imagining counterfactuals — the foundation of causal AI in drug discovery. Introduction: The Limits of Correlation in Drug Discovery Drug discovery today generates unprecedented volumes of data. Omics, imaging, electronic health records, and real
Esther Chen
Sep 76 min read


Vizuro Selected for Wet Lab Validation in Winter'24 Adaptyv Bio's EGFR Binder Design
Fig 1. Adaptyv Bio “Protein Design Competition Round2” Competition Overview Protein binding remains one of the most challenging aspects...

Yu-Feng Wei
Jan 103 min read


What’s next for drug discovery after AI won the 2024 Nobel Prize in Chemistry?
Key Takeaways: The 2024 Nobel Prize in Chemistry was awarded for groundbreaking advancements in computational protein structure...

Yu-Feng Wei
Oct 22, 20244 min read
bottom of page